Greater access to IPOs through OnMarket BookBuilds

amscot has partnered with OnMarket BookBuilds to provide our clients with even more investment opportunities. In addition to the exclusive capital raisings that amscot undertakes and offers to our clients, you can now take advantage of offers from OnMarket. Our association with OnMarket will allow you to bid directly on IPOs and have the shares allocated straight to your holdings at amscot. Through OnMarket our clients will also be able to access free research, management interviews and get notifications on upcoming IPOs.

OnMarket is Australia’s first online platform that lets all investors buy shares in IPOs free of any fees other than the cost of the shares. Since launching in October 2015 OnMarket has hosted 1 in 3 ASX IPOs, so we are obviously excited to be able to offer our clients access to this cutting-edge platform. For each offer hosted by OnMarket you get easy bidding & payment, free independent research, and a chance to 'meet the management' via exclusive video interviews. Best of all, when you invest in IPOs via OnMarket, any shares you buy can be allocated directly to your amscot Stockbroking account so you can manage your portfolio without disruption.

How does it work?

We will display the list of current offers from OnMarket on our website. If you see an offer that you want to invest in then click on the Bid Now button to apply for shares. You will leave amscot website and be redirected to our partner's (OnMarket) bidding platform where you will need to sign up with your Holder Identification Number (HIN). If you have already signed up then you will be taken straight to the bidding page for the selected offer.

It is important that you enter your HIN correctly when you set up your login at OnMarket. This will make for a seamless experience if you want your shares to be automatically allocated to your amscot account.

Current OnMarket Offers

IPO
Materials
$0.20
Size of Offer $4m - $6m
Minimum Bid $2,000.00
Opening Date 4/07/2019
Closing Date 21/10/2019

 

Update

The company has advised that a Supplementary Prospectus has been lodged and the offer has been extended until 21 October 2019.

Introduction

Tartana Resources Limited (ASX: TNA) is a zinc and copper exploration company with assets being the Tartana Copper and Zinc Project in northern Queensland and the Zeehan Zinc Slag Project in western Tasmania.  The Tartana Project is the flagship project. It comprises four mining leases which contains an open pit which was the source of copper oxide ore for historical copper sulphate production using heap leach pads and a solvent extraction/crystallisation plant, still on site

Past exploration on the mining leases has defined four separate exploration projects and mineralisation in each potentially relates to an interpreted deeper porphyry copper system. The projects are the Queen Grade Zinc Project comprising a zone of interpreted zinc skarn mineralisation, a Copper Oxide Project which is based on mineralisation evident within and around the existing open pit, a deeper Copper Sulphide Project below and to the north of the pit and lastly, the Valentino Copper/Gold/Silver/Cobalt Project which is further east but may also be related to the deeper sulphide mineralisation.

Recent work by the Company has involved defining JORC 2012 Exploration Targets for the Queen Grade Zinc Project and both the deeper Copper Sulphide and Valentino Projects.

Investment Highlights

  • Exploration potential – The Tartana Copper and Zinc Project is located in the prospective Chillagoe region and has previously operated as a mining operation and with further exploration, each of these Projects has potential for the Company to define copper or zinc resources.
  • Historical data – The Tartana Copper - Zinc Project has been sporadically explored over the years with historical drilling, geological and geophysical data available. The Zeehan slag dumps have been drilled by past explorers and the company has recently completed further drilling to upgrade the mineralisation to resource status.
  • Attractive commodities  - copper and zinc are two commodities with attractive supply and demand fundamentals
  • Granted mining tenements – The four tenements associated with the Tartana Project are long-dated Mining Lease, the Zeehan Slag tenement is under a newly granted Mining Lease and the Mt Hess and Amber Creek Tenements are granted exploration permits renewable in 2022.
  • Experienced management team with significant expertise in mineral projects, project development and corporate finance.

Offer overview

Tartana Resources Limited is looking to raise $4 million to $6 million.  The company proposes to use the funds raised from the Offer to:

  • undertake drilling on the projects within the Tartana Copper and Zinc Project mining leases;
  • advance the Zeehan Zinc Slag Project, commence initial exploration on the Mt Hess and Amber Creek Projects and undertake project generation;
  • Provide working capital; and
  • to pay for the variable costs of the Offer.

The Mining Projects

Tartana has a mission to become a significant copper and zinc company through development of its existing projects, acquisitions of new projects and exploration success.

The Tartana Project has been broken into four separate projects within the four mining leases and these are; Copper Oxide Project, Copper Sulphide Project, Queen Grade Zinc Project and the Valentino Copper/Gold/Silver/Cobalt Project. 

Tartana Copper and Zinc Project, North Queensland

The flagship project is located approximately 150 km west of Cairns and 40 km northwest of Chillagoe along the Burke Development Road.  This area hosts major porphyry and skarn related deposits including the Red Dome porphyry copper-gold skarn, the Mungana porphyry copper-gold-zinc-lead deposit, the King Vol high grade zinc skarn deposit and numerous smaller deposits along the belt.  Historically, copper mineralisation has been reported at Tartana Hill where small scale mining has occurred in the past as well as elsewhere across our leases.

Separately, zinc mineralisation is present in the Queen Grade Project within our mining leases, and has similarities with the zinc mineralisation in other projects in the Chillagoe region including the neighbouring King Vol Zinc mine.

 

Copper Sulphate Production and Copper Oxide Potential

The previous owner and operator treated copper oxide mineralisation in a small scale heap leach solvent extraction operation which produced high quality copper sulphate. The process involved mining shallow oxide copper ore in an existing and now partially rehabilitated open pit and which was stacked on the leach pads for leaching to produce copper sulphate for sale into the mining and agriculture industries. There is ample evidence that oxide copper material is still available in the base and walls of the pit and also in a zone extending 280 m north of the pit and we will focus some of our exploration work on quantifying this copper mineralisation (See Figure 5 and 6).

 

Figure 5 - Heap leach pads and Solvent Extraction plant.

 

Figure 6 - Copper Sulphate in one tonne bulka bags which has been produced by the previous owner and awaiting shipment).

 

Zeehan Zinc Slag Project, Western Tasmania.  Tartana’s wholly owned subsidiary, Intec Zeehan Residues Pty Ltd owns Mining Lease ML 3M/2017 located approximately 2.5 km south of the township of Zeehan in western Tasmania. This lease contains an old smelter site along with residue stockpiles of zinc-rich slag.

The Zeehan smelter operated intermittently from 1898 and 1948 recovering lead, silver and copper from the processing of locally mined ores and ore concentrates.  The Company recently implemented a 7-hole air core drilling programme to assist in verifying historical drilling data and to enable an upgrading of the mineralisation to a JORC 2012 Indicated Resource status

Tartana is investigating opportunities to monetise the zinc in the slag to provide working capital to finance other activities. And also to have the opportunity to improve the site in terms of its historical significance.  They have investigated a number of options which include:

  • Leaching the slag to recover the zinc. This includes leach testwork which has been carried out by Core Resources Pty Ltd, and demonstrates that high zinc recoveries are achievable in a leach process.
  • Slag sales to a third party processor in Europe. Samples have been collected and sent overseas for testing in a Waelz kiln in Europe.
  • Slag sales to local smelters. This has involved the collection of a 5,000 tonne bulk sample which has been trucked to the Port of Burnie. This bulk sample has been shipped to Nyrstar’s Port Pirie smelter in South Australia and been used in trial processing.

The Exploration Projects

Tartana has two exploration projects in Queensland which are held in the Company’s 100% held subsidiary, Oldfield Resources Pty Ltd.

Mt Hess Copper-Gold Project - The Mt Hess Project is located approximately 100 km southwest of Mackay. The project area covers part of the Gotthardt granodioritic intrusion which intrudes into the overlying Permian sediments of the Bowen Basin. Skarn and porpyhry copper mineralisation is associated with this intrusion and within the Mt Hess Project area there are numerous copper-gold prospects in an area north of the Gotthardt granodiorite.

Amber Creek Molybdenum-Tin-Tungsten Project - The Amber Creek Project is located 177 km southwest of Cairns and comprises an area covering a number of separate molybdenum, tin and tungsten prospects. These prospects are within the undifferentiated metamorphics which are probably related to the McDevitt Metamorphics which have been intruded by the Elizabeth Creek Granite.  Oldfield has conducted geological mapping along with soil and magnetic surveys over the area and has also identified several discrete mineralised vein structures. Tartana will implement an initial exploration programme focused on sampling these structures.

Commodity Outlook

Copper

Copper is often referred to as a bellwether of the markets and the supply/demand balance is often dominated by demand expectations which itself reflects the outlook for world economic growth but particularly with China. As well as copper demand in electric vehicles, stronger copper demand stems from new infrastructure projects in China and India including the expansion of their respective power grids and in China, the development of the high-speed rail network and domestic demand (air conditioners, etc.).

Zinc

According to the International Lead and Zinc Study Group, after increasing by 1.3% in 2018, global zinc mine production is forecast to rise by 6.2% to 13.48 million tonnes in 2019. New zinc supply has been dominated by Australian producers.  China is also a significant player in the zinc market as investment in infrastructure and any pick-up in construction could drive overall demand higher.

Management and Board

Tartana Resources Limited is led by a team which has extensive experience in geology, mining and metallurgical processing and product marketing as well as financial, technical and management experience in the resources industry.  These include:

  • Dr Stephen Bartrop (Executive Chairman) with more than 30 years’ experience covering periods in both the mining industry and financial sector. With a geology background, Steve has worked in exploration, feasibility and evaluation studies and mining in a range of commodities. In the financial sector, Steve has been involved in research, corporate transactions and IPOs spanning a period of more than 20 years, including senior roles at JPMorgan, Bankers Trust and Macquarie Equities.
  • Bruce Hills (Executive Director) is currently an Executive Director of Breakaway Investment Group Pty Limited which operates the Breakaway Private Equity Emerging Resources Fund. Bruce is a Director of a number of unlisted companies in the mining and financial services sectors including The Risk Board and Stibium Australia.
  • Peter Rohner (Executive Director) with over 30 years’ experience in the mining industry and has been involved in mineral processing technology development including development of the Jameson flotation cell, IsaMill fine grinding and more recently had significant involvement in further development of Glencore’s Albion Process (fine grind oxidative leach) technology.
  • Craig Nettelbeck (Non-Executive Director) successfully forged global relationships enabling him to negotiate numerous complex transactions before moving into the corporate advisory sector specialising in the agriculture, energy and mining sectors.
  • Robert Waring (Non-Executive Director) with over 40 years’ experience in financial accounting and company secretarial roles, principally in the resources industry.

Risks

You are encouraged to read the Prospectus carefully as it contains detailed information about the Company and the Offer. Like all investments, an investment in the Company carries risk. As set out in Section 9 of the prospectus, Tartana Resources Limited is subject to a range of risks, including but not limited to exploration and development, development of acquisition opportunities, valuation of tenements, dependence on key personnel and native title and land access risks.

 

Section 734(6) disclosure: The issuer of the securities is Tartana Resources Ltd ACN 126 905 726. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above).​

Breakaway Research Pty Ltd has provided only a distribution service to OnMarket using its database. Please note that Stephen Bartrop is a director of Tartana Resources and is also a director of Breakaway Research Pty Ltd.

OnMarket has a limited allocation. The offer may close early and the 'Pay By' dates may change. Bids over $10,000 may be scaled back more heavily. Duplicate bids under the same investment profile, investor name or residential address may be cancelled.

IPO
Biotech
$0.50
Size of Offer $20 million
Minimum Bid $2,000.00
Opening Date 8/10/2019
Closing Date 18/10/2019

The Cronos Australia Ltd IPO has closed for applications via OnMarket. 

 

OnMarket is receiving applications for the Cronos Australia Ltd IPO during the Exposure Period. More details here.

OnMarket has a limited allocation, and bids over $10,000 may be more heavily scaled back. The IPO may close early, and the Pay By date may change. Duplicate bids under the same investment profile, investor name or residential address may be cancelled.

The IPO is fully underwritten by Lead Manager, Bell Potter.

 

Introduction

Cronos Australia Ltd (ASX:CAU)* is a medicinal cannabis company that plans to enter the medicinal cannabis market in Australia with both THC and CBD cannabis products. Cronos Australia has secured all the necessary Australian licences to operate – including import and export licences. In addition to distributing the in-market brand PEACE NATURALS™, which is sold in Canada and Germany, Cronos Australia intends to also engage in product and brand development, outsourced manufacturing and distribution for Australia and target export markets in Asia (subject to legislative reform in those markets and Cronos Australia obtaining any required approvals and licences).

Cronos Australia was established as a 50/50 joint venture between a global cannabinoid company, Cronos Group Inc (dual listed – NASDAQ:CRON, TSX:CRON – with a market capitalisation of A$4.53 billion) and a Melbourne based private equity firm controlled by the two Executive Directors of Cronos Australia.

On 8 March 2019, Cronos Group Inc announced the closing of a C$2.4 billion strategic investment by Altria Group, Inc.

* subject to receipt of listing approval

Key Investment Highlights

  • Licences have been received from the relevant Australian authorities for Cronos Australia to import, export, cultivate, manufacture and research cannabis.
  • Access to Cronos Group Inc’s intellectual property, including a selection of cultivars from Cronos Group Inc’s genetic bank of approximately 140 cannabis cultivars, as well as licences in respect of certain trademarks, processes and designs, and access to know-how relating to marketing, licensing and design (subject to a licence agreement with Cronos Group Inc).
  • Route to early revenue through the proposed importation and sale of medicinal cannabis products.
  • ‘Asset light’ model, leveraging an outsourced cultivation and manufacturing model.
  • Focused on development of brands and products, particularly CBD Products, in partnership with appropriate creative and design agencies.
  • Supply, manufacture and research agreements in place with Mile High Labs, MediPharm Labs Australia, Peace Naturals Project and the Victorian Government’s AVS.
  • Business development function established in Hong Kong to undertake business development activities in Asian markets as the laws in relation to medicinal cannabis products in those markets continue to evolve.
  • Experienced leadership team in the global cannabis industry, as well as in high growth enterprises, marketing and regulation.

Offer Overview

Industry overview

Cronos Australia operates in the medicinal cannabis industry in Australia. Medicinal cannabis is a term that covers a broad range of products derived from the cannabis plant or the chemical compounds it produces, such as cannabinoids, that are used for the purposes of treating or alleviating the symptoms of a disease, ailment or injury. THC and CBD are the most abundant cannabinoids.

Current and Proposed Business Activities

Cronos Australia was formed to take advantage of opportunities relating to the emerging cannabis industry both domestically and internationally. The vision of Cronos Australia is to become a leading health and wellness company in the Asia Pacific region through the distribution of premium cannabis products.

Cronos Australia’s business model is focused on the creation of shareholder value through a number of interdependent strategic priorities as detailed below:

Cronos Australia Business Model Overview

img-responsive

To achieve this, the business model is based on a number of strategic pillars that define the growth strategy of Cronos Australia, including:

 

Medicinal Cannabis Licences

Licences issued by the Office of Drug Control (ODC) pursuant to the Narcotic Drugs Act 1967 (Cth) (ND Act) serve to determine who may legally conduct an activity (such as importation), while permits issued by the ODC specifically control the activity (such as the type, quantity and timing of products that may be imported).

To date, five Federal Government licences have been granted to a subsidiary of Cronos Australia by the ODC, including:

  • Medicinal Cannabis Licence (cultivation and production)
  • Cannabis Research Licence
  • Medicinal Cannabis Licence (Manufacturing)
  • Import Licence and Permits
  • Export Licence

A summary of the licences and expiration dates is provided in Section 3.3 of the prospectus.

Growth Strategy

Cronos Australia has a three-phase growth strategy*:

* The timeframes outlined for each phase are indicative and may change.

Key Relationships

Cronos Australia has established a number of key relationships that will assist in the execution of its business model:

  • Cronos Group Inc: The relationship with Cronos Group Inc brings with it the weight of a leader in the global cannabis industry with access to valuable intellectual property including medicinal cannabis brands, genetics and technical expertise. Cronos Global Holdings Inc is a major shareholder in Cronos Australia and Cronos Australia has entered into the IP Licence with Cronos Group Inc and the PEACE NATURALS Supply Agreement with Peace Naturals Project.
  • AVS: AVS is one of Australia’s leading biosciences facilities. Cronos Australia – Operations Pty Ltd has entered into the Technical Services Agreement for a number of key research and development services including the importation and propagation of cannabis genetic material.
  • Mile High Labs: Mile High Labs is a CBD ingredient manufacturing business. Its head office is located in the United States and it has an Asia-Pacific office in New Zealand. Mile High Labs supplies CBD and CBD infused products to companies across the United States and Europe. Cronos Australia – Operations Pty Ltd and Mile High Labs have executed the Mile High Labs Supply Agreement pursuant to which Mile High Labs may supply CBD Products to Cronos Australia.
  • MediPharm: MediPharm Labs Corp., a company domiciled in Canada, is a global leader in scaled, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, and is listed on the Toronto Stock Exchange. The company’s Australian venture, MediPharm Labs Australia, began in January 2017 following changes to Australia’s federal legislation allowing companies to produce medicinal cannabis products in Australia. Cronos Australia has entered into an agreement whereby MediPharm Labs Australia may supply cannabis goods or may manufacture certain cannabis products for Cronos Australia.
  • DHL: Cronos Australia – Operations Pty Ltd has entered into an agreement with DHL Supply Chain for transportation, logistics and warehousing services and also has a trading account in place with DHL Global Forwarding to handle international freight and customs clearance services on behalf of Cronos Australia. These arrangements are required to provide the logistical support to enable Cronos Australia to import medicinal cannabis products into Australia for distribution.
  • Sigma: Sigma is an Australian full-line wholesale and distribution business to branded and independent community pharmacies and to hospital pharmacies. Sigma pharmacy brands include Amcal, Discount Drug Stores (DDS), Guardian, Pharmasave and Chemist King. Cronos Australia – Operations Pty Ltd has entered into the Sigma MOU regarding the potential for Sigma to distribute Cronos Australia products.
  • Medicinal Cannabis Industry Australia (MCIA): MCIA is an Australian medicinal cannabis industry body. Cronos Australia was a founding member of the MCIA with Cann Group Limited (ASX:CAN), AusCann Group Holdings Limited (ASX:AC8), THC Global Group Limited (ASX:THC) and MedReleaf Australia, and through this forum Cronos Australia intends to play a key role in raising awareness of, and promoting, the medicinal cannabis industry in Australia.

Offer Overview

Cronos Australia is looking to issue up to 40,000,000 shares at an issue price of $0.50 to raise A$20 million (before expenses).  The Offer is fully underwritten by the Lead Manager, Bell Potter Securities Ltd.

The company proposes to use the funds raised from the offer for:

  • Product and business development;
  • Patient acquisition / practitioner engagement;
  • Brand creation, development and launch;
  • Contract manufacturing management;
  • Research and development activities;
  • Licensing and regulatory costs;
  • Inventory of finished products;
  • working capital and administration; and
  • Outstanding costs of the Offer

Key Board and Management

Shane Tanner – Independent Non-Executive Chairman

Shane is currently the Chairman of Paragon Care Limited (ASX:PGC) and Rhythm Biosciences Limited (ASX:RHY) and he is an Independent Non-Executive Director of Victory Offices Limited (ASX:VOL). Shane also has significant strategy and transaction experience through the Mayne Group via the IPO of the telecommunications company, Optus Communications. Shane holds Business and Finance qualifications from RMIT University and Swinburne University of Technology.

Rodney Cocks – Executive Director and Chief Executive Officer

Rodney is a Director of NewSouthern Capital, a private equity firm he co-founded which undertakes business in the real estate, energy and digital sectors. Prior to Cronos Australia, he was on the Senior Leadership Team at Linfox and was a Consultant at the Boston Consulting Group. Rodney also served on the Counter Narcotics Team of the British Embassy in Kabul, Afghanistan and with the United Nations in Afghanistan, Sri Lanka, Pakistan and Iraq. Army. Rodney holds a BComm from the University of Melbourne, LLB from the Queensland University of Technology, MBA from the Wharton School, University of Pennsylvania, MPA from the Harvard Kennedy School, Harvard University and is a Graduate of the Australian Institute of Company Directors and the Royal Military College, Duntroon.

Peter Righetti – Executive Director and Chief Operating Officer

Peter is a Director of NewSouthern Capital, a private equity firm he co-founded which undertakes business in the real estate, energy and digital sectors. Prior to NewSouthern Capital, he held senior commercial and leadership positions with private development and construction organisations. He was part of the executive team at ASX listed, Engenco Limited (ASX:EGN) and held senior development and project roles at construction companies including Metricon Group. Peter served as an Engineer Officer in the Australian Army.

He holds a BComm from Deakin University, LLB from the University of New England and is completing an LLM at the University of Melbourne.

Anna Burke AO – Independent Non-Executive Director

Anna served in the Australian Federal Parliament as the Member for Chisholm in the House of Representatives from 1998 to 2016, and was also the 28th Speaker of the Australian House of Representatives. Anna is also a full-time Member at the Administrative Appeal Tribunal. She also had extensive Committee service in the Federal Parliament, including Joint Statutory Committee on Corporations and Financial Services and House of Representatives Standing Committee on Economic, Finance and Public Administration. Anna holds a BA (Hons) and MComm (Hons) from the University of Melbourne. Anna was appointed as an Officer of the Order of Australia in January 2019.

Michael Gorenstein – Non-Executive Director

Michael Gorenstein is a Non-Executive Director of Cronos Australia. Mike is the Chairman, President and Chief Executive Officer of Cronos Group Inc (NASDAQ: CRON, TSX: CRON). Mike is also a co-founder and Member of Gotham Green Partners (Gotham Green). Before joining Cronos Group Inc, Mike was the VP and General Counsel at Alphabet Partners, LP, a New York City based multi-strategy investment management firm, focused on identifying mispriced assets across various industries, asset classes and geographies. Mike graduated from the University of Pennsylvania Law School with a JD, the Wharton School at University of Pennsylvania.

Jason Adler – Non-Executive Director

Jason Adler is a Director of Cronos Group Inc (NASDAQ: CRON, TSX: CRON), the co-founder and Managing Member of Gotham Green, a private equity firm focused primarily on early-stage investing in companies in the cannabis industry. Prior to co-founding Gotham Green, Jason was the co-founder and Chief Executive Officer of Alphabet Partners, LP, a New York City based multi-strategy investment management firm, focused on identifying mispriced assets across various industries, asset classes and geographies. Jason also founded Geronimo, LLC, a broker dealer and member of the American Stock Exchange, that made markets in equity options, and he began his career as a Market Maker at G&D Trading. Jason graduated with a B.A. from the University of Rhode Island.

Lior Harel – General Counsel and Company Secretary

Lior Harel is the General Counsel and Company Secretary of Cronos Australia. Prior to Cronos Australia he was the Chief Legal Counsel of SEEK.com.au (ASX:SEK) with coverage of SEEK’s Australian and Asian businesses. Prior to SEEK, Lior was the Chief Operating Officer and General Counsel of ecommerce and travel business, The Lux Group (cudo.com.au, luxuryescapes.com, deals.com.au). He commenced his career at leading Australian commercial law firm, Arnold Bloch Leibler, rising to Senior Associate in the Corporate/Commercial and Banking and Finance teams. Lior holds an LLB and a BA from the University of Melbourne.

Thomas Howitt – Chief Financial Officer

Thomas Howitt is the Chief Financial Officer of Cronos Australia. Prior to Cronos Australia he was the Chief Financial Officer of Global Kinetics Corporation a pre-IPO life sciences company, Chief Financial Officer and Company Secretary of Simavita (ASX:SVA, TSX-V:SV) a digital healthcare company, Chief Financial Officer and Company Secretary of Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE) a genetic testing company, Chief Financial Officer and Company Secretary of Intermoco Limited (formerly ASX:INT) a remote monitoring and control company, Chief Financial Officer and Company Secretary of Lowell Capital a privately held investment banking group and Manager at EY. Thomas holds a BComm from the University of Western Australia.

Risks

An investment in Cronos Australia is subject to a range of risks including but not limited to failure to maintain required licences, changes in law, growth prospects, supply chain interruption, access to IP and early stage risk. For more information read Section 6 of the Prospectus.  These risks should be considered in detail.

 

Exposure Period

OnMarket is receiving applications for the Cronos Australia Ltd IPO during the Exposure Period.  Applications will be not be processed until the completion of the Exposure Period and no preference will be conferred on applications received during the exposure period.

If a replacement or supplementary prospectus is issued, this will be provided to you along with the opportunity to withdraw your application.

 

Section 734(6) disclosure: The issuer of the securities is Cronos Australia Limited ACN 629 071 594. The securities to be issued are ordinary shares. The disclosure document for the offer can be obtained by clicking on the link above. The offers of the securities are made in, or accompanied by, a copy of the disclosure document. Investors should consider the disclosure document in deciding whether to acquire the securities. Anyone who wants to acquire the securities will need to complete the application form that will be in or will accompany the disclosure document (which can be done via the electronic application form which will become available by clicking the bid button above).

 

OnMarket has a limited allocation. The offer may close early and the 'Pay By' dates may change. Bids over $5,000 may be scaled back more heavily. Duplicate bids under the same investment profile, investor name or residential address may be cancelled.

Disclaimer: All information on this section is of a general nature. Before making any investment decision, please seek the relevant advice.

Back to top